SureTrader Advertisement Advertisement
Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator nathanial, Inoviorulez
Search This Board:
Last Post: 11/30/2015 11:13:40 PM - Followers: 155 - Board type: Free - Posts Today: 0

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.


RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.


This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...


June 9, 2015 RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform

Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#3098   Should go over $2 IMO. Also depends on Titan V 11/30/15 11:13:40 PM
#3097   Yes. $1.00 and then some. Imagine if The Other Guy 11/30/15 09:05:28 PM
#3096   Let's hope something is in the works. InternetForumUser 11/30/15 07:30:42 PM
#3095   Volume was decent early but dropped off as The Other Guy 11/30/15 06:22:26 PM
#3094   Quite possible we could start to see some Inoviorulez 11/30/15 02:30:26 PM
#3093   RXII getting a little love today! jaytea 11/30/15 12:07:16 PM
#3092   Thanks much for the info. cardvic 11/25/15 02:05:19 AM
#3091   Short interest up about 100k for the latest period. The Other Guy 11/24/15 04:24:55 PM
#3090   It RSed 1:30 when it was trading around Titan V 11/24/15 08:11:30 AM
#3089   I took a small position on RXII a cardvic 11/24/15 02:16:38 AM
#3088   Gotcha. Thanks Bio. Titan V 11/19/15 10:54:46 AM
#3087   The company is only in phase 2a. The Inoviorulez 11/18/15 11:31:13 PM
#3086   It would be a material event either way. The Other Guy 11/18/15 12:43:19 PM
#3085   I would think so. As the company claims Titan V 11/18/15 11:42:52 AM
#3084   Would that move the needle? The Other Guy 11/18/15 11:31:11 AM
#3083   Is there going to be a phase 3 Titan V 11/18/15 10:46:41 AM
#3082   I tend to agree. I listened to the The Other Guy 11/18/15 10:25:04 AM
#3081   That's what I'm thinking, risk reward here seems Phantom Lord 11/17/15 01:31:14 PM
#3080   Ok phantom. Good luck to you. Nice support Rogerthat1 11/17/15 01:27:21 PM
#3079   No idea, only thing I can think of Phantom Lord 11/17/15 01:26:26 PM
#3078   Good to know. So why the heck is Rogerthat1 11/17/15 01:21:06 PM
#3077   They got a 180 day extension on Nov Phantom Lord 11/17/15 12:14:01 PM
#3076 Titan V 11/17/15 12:09:41 PM
#3075   Is this pos delisted already or just about Rogerthat1 11/17/15 11:27:40 AM
#3074   We need a news release of partnership like million_dollar_mafia 11/16/15 02:39:08 PM
#3073   RNAi for Therapeutic Applications: Technology and Market Forecast Titan V 11/16/15 10:14:50 AM
#3072   Q3 2015 Earnings Conference Call November 12, 2015, 16:30 tomsylver 11/12/15 11:09:17 PM
#3071   RXi Pharmaceuticals Reports Third Quarter 2015 Financial Results tomsylver 11/12/15 11:06:53 PM
#3070   Speaking of short interest; virtually unchanged. The Other Guy 11/11/15 09:12:04 AM
#3069   Not really. Will probably update on when Samcyrpone Inoviorulez 11/10/15 09:24:18 PM
#3068   Not really. Will probably update on when Samcyrpone Inoviorulez 11/10/15 09:24:18 PM
#3067   Any expectations from the CC this Thursday? The Other Guy 11/10/15 05:00:39 PM
#3066   Hope they are able to really maximize in Titan V 11/10/15 09:44:15 AM
#3065   Me too!! I really like the potential of Burrhead1 11/10/15 09:25:45 AM
#3064   It sure can! I'm hoping Geert will not Titan V 11/10/15 09:19:55 AM
#3063   Same here Titan but I sold all of Burrhead1 11/10/15 09:09:54 AM
#3062   ACTC used to be my biggest bio holding Titan V 11/10/15 09:06:36 AM
#3061   They are being bought out at what most Burrhead1 11/10/15 09:00:30 AM
#3060   Explain? million_dollar_mafia 11/10/15 08:55:29 AM
#3059   There sure are some pissed off folks on Burrhead1 11/10/15 07:59:53 AM
#3058   I choose to call it an Apollo rocket Burrhead1 11/06/15 12:03:13 PM
#3057   11% increase in short interest in a two The Other Guy 11/06/15 11:55:03 AM
#3056   I don't think I would call 500k heavy shorting. Phantom Lord 11/06/15 11:20:13 AM
#3055   One only needs to look at the short The Other Guy 11/06/15 11:13:45 AM
#3054   Bollinger bands coiling or what million_dollar_mafia 11/06/15 11:01:58 AM
#3053   Do you have any evidence to back this Phantom Lord 11/05/15 06:31:51 PM
#3052   It's being heavily shorted just keep adding, average Inoviorulez 11/05/15 06:08:36 PM
#3051   I think everyone was expecting this news. Phantom Lord 11/05/15 06:07:11 PM
#3050   Really another news day and were red. Like clockwork million_dollar_mafia 11/05/15 04:52:54 PM
#3049   More news - Edison Research firm in London Inoviorulez 11/05/15 08:31:25 AM